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Abstract 
The heart of subjects with hypertension and cardiac hypertrophy is more vulnerable to 
ischemia/reperfusion injury (IRI). Here we discuss the main mechanisms of IRI and possible targets 
for cardioprotection. In particular, we consider the viewpoint that hypertension and cardiac 
hypertrophy may act synergistically in increasing the predisposition to cardiovascular accidents and 
in worsening IRI. There is no doubt that hypertrophic hearts may be redirected to be less vulnerable 
to IRI. Some experimental evidences suggest that anti-hypertensive drugs may have beneficial 
effects, some of which are not directly related to hypertension lowering effect. However, more 
thorough experimental and clinical studies are necessary to understand the mechanisms and to 
maximize the beneficial effects of reperfusion after a heart attack in the presence of comorbidities, 
such as hypertension and cardiac hypertrophy. 
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Hypertension is estimated to occur in about 30% young adults, increasing to about 60% for those 
over 60 and to 75% in older than 70 
1
. In about 90% of patients the cause of hypertension is 
unknown; actually they suffer the so-called essential hypertension. In about 20-30% of hypertensive 
patients left ventricular hypertrophy (LVH) is observed, which is associated with a poor prognosis. 
Thus hypertension is the most common cause of LVH and cardiovascular accidents 
2,3
. The 
prevalence of LVH is even higher in aged patients 
3,4
. In this mini-review, we briefly consider 
hypertension and the compensated LVH, i.e., before the onset of overt cardiac failure, as a risk 
factor. We also discuss hypertension and LVH effects on responses to ischemia/reperfusion, and the 
effectiveness of cardioprotective strategies in these conditions. 
 
In hypertrophic hearts the total O2 consumption is high and any reduction of the coronary flow has 
more severe consequences. The narrowing of a coronary artery that produces no symptoms when 
the heart size is normal can produce acute myocardial infarction (AMI) when the heart is enlarged 
or hypertrophic. In the absence of coronary stenosis, the coronary flow reserve may decrease for 
several reasons, including a decrease of the vasodilatory reserve and an increase of the basal flow 
due to cardiac hypertrophy and small vessel disease, typical of hypertension 
5,6
. 
Moreover, hypertension increases the incidence of atherosclerosis and myocardial infarction and 
these conditions are common even when the heart is not hypertrophic. In the long period, the ability 
of the heart to meet the increased peripheral resistance is overcome, and heart failure occurs. 
Hypertensive subjects are also predisposed to cerebral vessels thrombosis and hemorrhage. A 
further complication is kidney failure. However, the incidence of heart failure, stroke, and kidney 
failure can be greatly reduced by the active treatment of hypertension, even when hypertension is 
relatively moderate. At present, essential hypertension is treatable, but not curable. An effective 
lowering of blood pressure may be produced by different drugs which have diverse mechanisms of 
action: diuretics, inhibitors of converting enzyme of angiotensin, calcium channel antagonists, and 
blockers of angiotensin, α-adrenergic or β-adrenergic receptors. Experimentally, inhibition of 
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aldosterone has also been observed to prevent fibrosis and myocardial hypertrophy due to a 
prolonged adrenergic action on the heart 
7
. 
Myocardial infarction is usually due to the occlusion of a coronary branch following atherosclerotic 
plaque rupture. Usually, in order to have necrosis, ischemia should last about 20-30 minutes, but 
patients may die because of tachyarrythmias and ventricular fibrillation before irreversible injury 
has time to appear. Interestingly, along with increased interstitial fibrosis, the hypertrophic 
myocardium may display prolongation of the cardiac action potential and abnormalities in 
individual currents, such as ICaL, INa, and Ito, which may predispose to arrhythmias, through 
different mechanisms 
8-11
. Importantly, in epidemiological studies, sudden cardiac death is closely 
associated with hypertensive LVH 
12
. 
Of note, if the occluded artery is reopened, the damage caused by ischemia is exacerbated in the 
first minutes of a subsequent reperfusion. It follows that the reopening of an occluded coronary 
artery is paradoxically a cause of worsening of the damage, leading to a greater extension of the 
infarcted tissue. To emphasize the role of reperfusion injury in myocardial damage, this 
phenomenon is called ischemia-reperfusion injury (IRI). 
 
The IRI affects both the myocardium and the coronary vessels. Vascular damage comprises the 
acute endothelial dysfunction and its consequences. Indeed, not only is coronary vasculature 
affected by atherosclerotic disease, but it is also injured after myocardial ischemia/reperfusion. 
Damaged vessels display edema, due to increased vascular permeability, as well as endothelial 
dysfunction and impaired vasomotility. Often atherothrombotic debris are the cause of 
microembolization leading to stasis with intravascular cell aggregates, and finally, to capillary 
destruction with hemorrhage. In the clinical scenario, the so-called no-reflow phenomenon (a 
reduced or absent reperfusion that occurs after the end of ischemia in a previously patent vessel) 
often occurs after artery reopening, and this is a worrying prognostic event 
13
.  
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Some mechanisms of myocardial damage, such as necrosis and apoptosis, initiate during the period 
of ischemia and worsen during the first minutes of reperfusion. Other mechanisms of myocardial 
injury and vascular damage occur only in the first minutes of reperfusion. The overall result of IRI 
is represented by necrosis and apoptosis, as well as a transient reduction of contractility of surviving 
myocardium (myocardial stunning). This is in part due to the presence of non-necrotic tissue no 
longer able to contract, or contracting with less force. Stunning can last from minutes to days, in 
relation to the severity of the preceding ischemia and in relation to the severity of reperfusion 
injury. 
The myocardial damage from IRI is due in large part to the long-lasting opening of the so-called 
mitochondrial permeability transition pore (mPTP) and the consequent explosive swelling of the 
cells. The mPTPs allow the passage of molecules of weight less than 1500 Dalton and their opening 
leads to swelling of mitochondria and cell death 
14
. At the beginning of reperfusion, the opening of 
mPTP is the consequence of the worsening of the Ca
2 +
 overload and of the production of reactive 
oxygen species (ROS).  
The cellular Ca
2+
 overload is also responsible for the contraction of the heart in the so-called 
contracture, that is the incomplete diastolic relaxation of the myocardium that results in an increase 
of the diastolic ventricular pressure. 
Another phenomenon responsible of IRI is the so-called pH paradox, that is the consequence of pH 
recovery from acidosis that occurs during ischemia, when the cellular pH drops inhibiting 
hydrolytic enzymes, such as phospholipase and proteases, which otherwise can damage the 
sarcolemma. In this sense, acidosis plays a protective role. At the onset of reperfusion instead the 
pH returns back to normal, reaching the optimum level for the action of the aforementioned 
enzymes that can target cell membranes causing the membrane rupture. 
The vascular reperfusion injury is also due to the lack of production of nitric oxide (NO) by the 
endothelium at the end of ischemia. As a result of NO deficiency we can observe vasoconstriction, 
platelet aggregation and activation of cell adhesion molecules or cellular adhesion molecules 
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(CAM), which favor the interaction between leukocytes and endothelial cells. The main CAM 
molecules involved in this mechanism are: selectins (P, L, E), integrins (CD11, CD18) and 
immunoglobulins such as intracellular adhesion molecule-1 (ICAM-1), the vascular cell adhesion 
molecule-1 (VCAM -1) and the platelet endothelial cell adhesion molecule-1 (PECAM-1). 
The aggregation of platelet and leukocyte adhesion to endothelial cells can lead to a reduction in the 
sectional area of small vessels with an increase in the flow resistance; however, this area reduction 
is exacerbated by the vasoconstriction due to NO deficiency. The concomitant presence of these 
factors can be the cause of the no reflow phenomenon, above described. It is obvious that this 
phenomenon can be the basis of a further worsening of myocardial damage. 
 
As said, IRI may be exaggerated by myocardial hypertrophy (Fig. 1). Actually, at the beginning of 
hypertrophy the heart may be more resistant to ischemic injury. However, this protection is lost a 
few weeks afterwards, and IRI is increased as hypertrophy develops 
15,16
. Mølgaard et al.
17
 have 
recently confirmed that hearts from spontaneous hypertensive stroke-prone rats with LVH are more 
susceptible to IRI and propose mitochondrial complexes III and IV as possible targets of the heart 
increased vulnerability. Already in the nineties, biochemical and metabolic modifications have been 
proposed as explanations for this increased susceptibility to IRI. Among such modifications, 
alterations in mitochondrial energetics, ATP production, glycolytic metabolism and lactate 
accumulation during ischemia are included 
18-20
. 
Clearly, chronic models of hypertrophy better reflect the clinical situation of hypertension leading 
to cardiac hypertrophy. We have shown that sub-chronic use of high concentrations of nandrolone, 
improves post-ischemic cardiac function in postconditioned hearts. However, chronic treatment 
with nandrolone induces marked myocardial hypertrophy, increases cardiac susceptibility to IRI and 
abolishes the possibility to induce postconditioning protection 
15,16
, a protection obtained with brief 
periods of ischemia (a few seconds) at the beginning of reperfusion 
21-23
. Actually, in animal 
experiments, local and remote ischemic pre-, per- and post-conditioning not only reduce 
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cardiomyocyte death, but also the typical events of coronary vascular injury, such as no-reflow 
phenomenon
24
. Moreover some drugs may activate signal transduction pathway typical of 
conditioning protocols. However, the translation of these protective interventions to clinical practice 
has been disappointing to date 
25,26
.  
 
Interactions between drugs and risk factors complicate the scenario. Angiotensin converting 
enzyme inhibitors (ACE-I) are widely used as antihypertensive drugs and were shown to prolong 
patients survival after myocardial ischemia 
27-29
. In addition to reducing the formation of 
angiotensin II, ACE-I reduce the degradation of kinins thus prolonging their activity 
30
. This 
prolonged activity on B2 receptors makes ACE-I particularly interesting in the context of IRI, since, 
by interfering with the B2 receptors 
31
 the heart responsiveness to cardioprotective interventions 
could be altered 
32,33
. Yet, ACE-I have been shown to reduce cardiac hypertrophy and to be 
cardioprotective per se 
27-30
. Actually, we have shown that in rats infarct size was larger in the 
presence of cardiac hypertrophy due to hypertension when compared to hearts of normotensive 
animals subjected to ischemia/reperfusion. Moreover, we have shown that a postconditioning 
protocol, which is able to induce cardioprotection against infarct size in normotensive rats, is not 
protective in hearts of hypertensive animals. Intriguingly, the postconditioning protocol does not 
add protective effects to the protection already provided by chronic Captopril treatment 
34
. Recently 
an experimental study demonstrated that preventive treatment with either cardosten, enalapril, or 
losartan can attenuate LVH development in infarction-induced heart failure in rats 
35
 . 
Overall, it seems that in hypertensive LVH before the onset of functional decompensation, 
conditioning cardioprotective mechanisms remain intact or are even up-regulated. Only the 
progression of LVH towards a decompensated state may compromise the possibility of protection. 
Only a few drugs (e.g., exenatide, esmolol, metoprolol and brain natriuretic peptide) have 
demonstrated some satisfactory effectiveness in reducing infarct size in patients that underwent 
reperfusion after acute myocardial infarction. Nevertheless, also for these drugs more pre-clinical 
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and clinical studies are necessary, as little information on their mechanism of action in the presence 
of comorbidities or on their impact on the post-ischemic coronary circulation is available. 
Some experimental data suggest that the concomitant presence of conditions such as age, 
hypercholesterolemia, diabetes, and hypertension, rather than LVH per se, is responsible of infarct 
size exacerbation and limitation of cardioprotective strategies’ effectiveness 36,37. Interestingly, in 
patients with multiple risk factors (high blood pressure, smoking, dyslipidemia, and diabetes) and a 
mean age of approximately 60 years, ischemic conditioning may reduce IRI and improve the 
patient's prognosis 
38,39
. Yet, it is not clear whether this discrepancy between studies is due to drug 
interactions, to the compresence of hypertension and LVH or to other reasons 
40
.  
Overall, it seems clear that the concomitant presence of high blood pressure and LVH is a 
dangerous condition. Treating hypertension, especially with ACE antagonists, regardless of blood 
pressure lowering and/or of LVH regression, may be useful to reduce the risk and the damage of 
ischemia and reperfusion, at least in animal experiments 
36
 .Whether this treatment is sufficient in 
humans to lower the risk and the ischemia/reperfusion damage has not been ascertained yet. 
Recently, chronic pretreatment with angiotensin receptor blockers has been associated with the 
reduction of the no-reflow phenomenon in 276 hypertensive patients with reperfused AMI. It seems 
that this treatment could preserve microvascular integrity after AMI. Also these beneficial effects 
seem not directly related to hypertension lowering function 
41
. It is likely that these beneficial 
effects are due to the so-called pleiotropic effects. Indeed, it has been reported that telmisartan may 
protect against microvascular dysfunction during myocardial IRI in rabbits, by activating 
peroxisome proliferator-activated receptor gamma 
42
.  
 
In conclusion, it is not surprising that a variation (ranging from highly protective to neutral and 
even negative results) in the magnitude of myocardial salvage can be observed among clinical 
studies testing cardioprotective strategies. In fact, similar to IRI, cardioprotective interventions may 
also be influenced by a number of conditions. Here, particularly relevant are the following 
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variables: 1) the duration of ischemia, 2) the extension of the area at risk; 3) the velocity and 
extension of artery reopening; 4) the presence of comorbidities, such as cardiac hypertrophy, 
hypertension and diabetes; 5) the therapies already used by the patients; to name only a few of the 
variables in play that are not easy to keep under the control of the physicians in the ‘clinical arena’.  
Relevant to the topic of this short commentary is the fact that hypertension and LVH may act 
synergistically in increasing the predisposition to cardiovascular accident and worsening of IRI. Of 
course, technical complications in the reperfusion strategies cannot be ignored, and more thorough 
experimental and clinical studies are necessary to understand the mechanisms of protection and to 
maximize the beneficial effects of reperfusion after an infarction in the presence of comorbidities 
such as hypertension and cardiac hypertrophy. 
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Figure legend 
Fig. 1. The concomitant presence of hypertension and cardiac hypertrophy predisposes to 
cardiovascular accidents and worsening of damage from ischemia/reperfusion injury (IRI). 
Some anti-hypertensive drugs, regardless of lowering in blood pressure, can reduce the 
consequences of IRI. The question mark indicates that the mechanisms of this protective effect 
are unknown. 
 
